Gordon Sangster to Join Codexis as Senior Vice President & Chief Financial Officer

Gordon Sangster to Join Codexis as Senior Vice President & Chief Financial
Officer

REDWOOD CITY, Calif., July 28, 2014 (GLOBE NEWSWIRE) -- Codexis, Inc.
(Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and
fine chemical industries, today announced that Gordon Sangster has agreed to
join Codexis as Senior Vice President & Chief Financial Officer. Gordon, who
will start on August 18, 2014, will manage all aspects of Codexis' financial
and accounting functions and will report to John Nicols, President & Chief
Executive Officer.

"Gordon brings over twenty years of experience in the biotechnology and life
sciences industry to Codexis, and given his multiple public-company CFO roles,
I am confident that he will step in seamlessly to help drive Codexis' success
and growth going forward," stated John Nicols. "Gordon's articulate, engaging
style will bring energy and direction to our investor relations and corporate
communications efforts, which will be especially important for Codexis
following our recent announcement of the groundbreaking multi-year license and
collaboration agreement with GSK."

"I am thrilled to join Codexis at this exciting time in the company's growth
and look forward to working with John, the entire management team and the
Board to drive the company's future success and to enhance value for our
investors," Gordon Sangster stated.

Prior to signing with Codexis, Mr. Sangster has served as Chief Financial
Officer at multiple public and private life science companies for the last
fourteen years. From October 2011 until July 2014, Mr. Sangster served as
Chief Financial Officer of Nitinol Devices & Components, a private medical
device manufacturer. Prior to that role, Mr. Sangster was Chief Financial
Officer of ITC Nexus-Dx, a private medical device company that focused on
point-of-care diagnostics, from October 2010 to July 2011. From November 2007
to October 2010, Mr. Sangster was Chief Financial Officer of Micrus
Endovascular, a publicly traded medical device company that was acquired by
Johnson & Johnson for $480 million. From 2006 to 2007, Mr. Sangster was also
Chief Financial Officer of HemoSense, Inc., a publicly traded medical device
company which was acquired by Alere. Prior to that role, Mr. Sangster was
Chief Financial Officer of AP Pharma, a publicly traded biotech company, from
2000 to 2006. Prior to his Chief Financial Officer roles, Mr. Sangster held
roles of increasing responsibility in finance at AP Pharma, Raychem,
CooperVision and Levi Strauss.

Mr. Sangster is a member of the Institute of Chartered Accountants in England
and Wales, and is a native of Edinburgh, Scotland.

About Codexis, Inc.

Codexis, Inc. is a leading developer of biocatalysts for pharmaceutical and
fine chemical production. Codexis' proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for rapid,
cost-effective and sustainable process development – from research to
manufacturing. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis'
ability to grow its business in the future and the ability of Mr. Sangster to
integrate into Codexis and succeed as Chief Financial Officer. You should not
place undue reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties and other factors that are, in some
cases, beyond Codexis' control and that could materially affect actual
results. Factors that could materially affect actual results include Codexis'
dependence on its collaborators; Codexis' dependence on a limited number of
products and customers; potential adverse effects to Codexis' business if its
customers' pharmaceutical products are not received well in the markets; and
Codexis' ability to retain key personnel. Additional factors that could
materially affect actual results can be found in Codexis' Annual Report on
Form 10-K filed with the Securities and Exchange Commission on March 13, 2014,
including under the caption "Risk Factors." Codexis expressly disclaims any
intent or obligation to update these forward-looking statements, except as
required by law.

CONTACT: Codexis Contacts:
        
         Investors:
         Mike Rice, 646-597-6987
         mrice@lifesciadvisors.com
        
         Media:
         Kate Whelan, +44 161 817 5008
         kate.whelan@notchcommunications.co.uk
 
Press spacebar to pause and continue. Press esc to stop.